生命周期管理 (LCM) 可通过增加收入和可能实现的收入多元化，大幅增加资产的商业价值。生物制药公司会做出一些重要抉择，比如优先考虑市场上核心产品的潜在适应症、配方和给药系统，决定如何分配资源以实现这些目标，确定发布时间和顺序等。
Our teams bring decision making, scientific, commercial, regulatory, geographical and domain expertise to help our clients make difficult trade-offs in their decision-making.
We assist our clients in taking LCM decisions by helping ideate options for additional value creation by means of product reformulation, combination or delivery. We assess the value and risk in these options to combat genericization, as well as indication extensions or “fighter brand” development. We then perform the financial analysis to prioritize allocation of R&D and commercial resources to opportunities to provide the maximum “bang for the buck”.
We make these trade-offs explicit by quantifying the full range of outcomes for each choice and transition of value and risk among choices.
客户在其资产生命周期的各个阶段都可以与我们接洽，在拟定计划、制定备选方案、开展财务评估并最终做出决策方面获得帮助。